gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure

Roberta D'Arrigo, Massimo Ciccozzi, Caterina Gori, Stefania Montieri, Stefano Aquaro, Rita Bellagamba, Evangelo Boumis, Giovanni Di Perri, Daniele Pizzi, Andrea Antinori, Giovanni Rezza, Carlo Federico Perno

Research output: Contribution to journalArticle


Enfuvirtide is the first of a new class of antiretroviral drugs that inhibits HIV entry. It is a 36 amino acid synthetic peptide that mimics the HR2 region of the HIV-1 gp41, preventing the fusion of viral and cellular membranes. Up to now, enfuvirtide was designed based on the HIV-1 B-subtype gp41, and resistance mutations to the fusion inhibitor have been investigated primarily in individuals infected with this subtype. To fill the gap, we analyzed the full length gp41 protein sequence of HIV-1 non-B strains from individuals receiving enfuvirtide-containing regimens. No primary resistance to the enfuvirtide binding domain (36-45 residues) was found. Resistance mutations were detected at follow-up visits and were comparable to those described among B-subtype HIV-1-infected patients; no sequence changes were detected in crucial HR1/HR2 gp41 sites such as the cytotoxic T lymphocyte epitope, cysteine loop, ectodomain, and 5-helix interaction and binding region.

Original languageEnglish
Pages (from-to)1296-1302
Number of pages7
JournalAIDS Research and Human Retroviruses
Issue number10
Publication statusPublished - Oct 2007


ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this